Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study

• Published in: Cardiovascular diabetology 2019-04, Vol.18 (1), p.52-52, Article 52
• Main Authors: Zhang, Lisha, Xu, Chenbo, Liu, Junhui, Bai, Xiaofang, Li, Ruifeng, Wang, Lijun, Zhou, Juan, Wu, Yue, Yuan, Zuyi
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - diagnosis; Acute Coronary Syndrome - mortality; Acute Coronary Syndrome - surgery; Acute coronary syndromes; Aged; Angioplasty; Biomarkers - blood; Blood Glucose - analysis; Cardiovascular disease; China; Cohort analysis; Coronary artery; Coronary artery disease; Diabetes mellitus; Diabetes Mellitus - blood; Diabetes Mellitus - diagnosis; Diabetes Mellitus - mortality; Fasting blood glucose; Female; Fibrinogen; Fibrinogen - analysis; Glucose; Glucose metabolism; Glycated Hemoglobin A - analysis; HbA1c; Health risk assessment; Heart diseases; Hemoglobin; Humans; Male; Middle Aged; Mortality; Original Investigation; Percutaneous coronary intervention; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - mortality; Prospective Studies; Regression analysis; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-019-0858-5

Despite revascularisation, a large proportion of acute coronary syndrome (ACS) patients continue to experience major adverse cardiovascular events (MACEs), which are worsened by diabetes mellitus (DM). Fibrinogen (FIB) is a risk factor for MACEs in coronary artery disease and often elevated in DM. However, the relationships between FIB, glucose metabolism (haemoglobin A1c [HbA1c] and fasting blood glucose [FBG]) and MACEs following percutaneous coronary intervention (PCI) in DM, non-DM or whole patients with ACS remains unknown. A total of 411 ACS patients undergoing PCI were enrolled in this study. We compared baseline FIB levels between DM (n = 103) and non-DM (n = 308) patients and divided participants into three groups according to FIB level, i.e. FIB-L, FIB-M and FIB-H, to compare baseline characteristics and MACEs. Linear regression analysis of the relationship between glucose metabolism and FIB, Cox regression, survival and landmark analyses of MACEs were also performed over a median of 27.55 months of follow-up. Patients with DM had higher FIB levels than non-DM patients (3.56 ± 0.99 mg/dL vs. 3.34 ± 0.80 mg/dL, P